Overview

Regorafenib 40 mg is positioned after a tumor has progressed on anti-VEGF therapy, using a wider kinase blockade plus structured supportive care to regain disease control. Its contribution is clearest as a sequenced option when earlier targeted lines have failed.

How It Works

Regorafenib inhibits VEGFR 1–3, TIE2, KIT, RET, and several other kinases involved in angiogenesis and stromal signaling. After a tumor escapes bevacizumab or first-line TKIs, this broader blockade hits residual angiogenic and oncogenic pathways that the prior agent missed. The clinical effect is maximized when paired with proactive management of hand-foot skin reaction and hypertension, so the regimen is as much about combination with supportive care as with the drug itself.

Indications

It is indicated for metastatic colorectal cancer previously treated with fluoropyrimidine, anti-VEGF, and anti-EGFR (where RAS wild-type) therapy, and for refractory GIST and hepatocellular carcinoma after sorafenib. These are late-line settings where sequencing and toxicity support define success. In colorectal cancer the sequence after anti-VEGF and anti-EGFR therapy is fixed by label, so line tracking drives appropriate use. Targeting TIE2 alongside VEGF receptors interferes with vessel maturation rather than only formation, which contributes to activity after prior anti-angiogenic therapy.

Dosage & Administration

The oral dose is 160 mg daily for three weeks of a four-week cycle, built from 40 mg tablets, with each box containing 28 tablets. Initiation at the full 40 mg-strength daily load and careful titration helps manage skin and blood-pressure toxicities during the active weeks.

Storage & Sourcing

Store tablets below 30°C in the original blister, dry and protected from light. Being an oral TKI it needs no cold chain, but continuous therapy means strict expiry rotation and humidity-controlled storage protect uninterrupted supply. The three-weeks-on structure means a 28-tablet box covers the active days with a planned recovery week, which simplifies stock planning for pharmacies.

FAQ

Q: Why is Regorafenib used after anti-VEGF failure? A: It blocks a wider kinase set including VEGFR, TIE2, KIT, and RET, covering angiogenic and stromal pathways that bevacizumab or earlier TKIs no longer control.

Q: How does supportive care function as part of the regimen? A: Proactive treatment of hand-foot skin reaction and hypertension lets patients stay on the active three-week dosing, turning toxicity management into a combination component.

Q: Why is Regorafenib initiated at the 40 mg tablet strength rather than split dosing? A: Four 40 mg tablets deliver the 160 mg daily load for the three active weeks, and the 28-tablet box covers those on-treatment days with a planned recovery week.